{"doc_id": "33676596", "type of study": "Therapy", "title": "", "abstract": "Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis (PReGo): a randomised, placebo-controlled, crossover trial.\nBacterial sexually transmitted infections (STIs) are highly prevalent among men who have sex with men who use HIV pre-exposure prophylaxis (PrEP), which leads to antimicrobial consumption linked to the emergence of antimicrobial resistance.\nWe aimed to assess use of an antiseptic mouthwash as an antibiotic sparing approach to prevent STIs.\nWe invited people using PrEP who had an STI in the past 24 months to participate in this single-centre, randomised, double-blind, placebo-controlled, AB/BA crossover superiority trial at the Institute of Tropical Medicine in Antwerp, Belgium.\nUsing block randomisation (block size eight), participants were assigned (1:1) to first receive Listerine Cool Mint or a placebo mouthwash.\nThey were required to use the study mouthwashes daily and before and after sex for 3 months each and to ask their sexual partners to use the mouthwash before and after sex.\nParticipants were screened every 3 months for syphilis, chlamydia, and gonorrhoea at the oropharynx, anorectum, and urethra.\nThe primary outcome was combined incidence of these STIs during each 3-month period, assessed in the intention-to-treat population, which included all participants who completed at least the first 3-month period.\nSafety was assessed as a secondary outcome.\nThis trial is registered with Clinicaltrials.gov, NCT03881007.\nBetween April 2, 2019, and March 13, 2020, 343 participants were enrolled: 172 in the Listerine followed by placebo (Listerine-placebo) group and 171 in the placebo followed by Listerine (placebo-Listerine) group.\nThe trial was terminated prematurely because of the COVID-19 pandemic.\n151 participants completed the entire study, and 89 completed only the first 3-month period.\n31 participants withdrew consent, ten were lost to follow-up, and one acquired HIV.\nIn the Listerine-placebo group, the STI incidence rate was 140\u00b74 per 100 person-years during the Listerine period, and 102\u00b76 per 100 person-years during the placebo period.\nIn the placebo-Listerine arm, the STI incidence rate was 133\u00b79 per 100 person-years during the placebo period, and 147\u00b75 per 100 person-years during the Listerine period.\nWe did not find that Listerine significantly reduced STI incidence (IRR 1\u00b717, 95% CI 0\u00b784-1\u00b764).\nNumbers of adverse events were not significantly higher than at baseline and were similar while using Listerine and placebo.\nFour serious adverse events (one HIV-infection, one severe depression, one Ludwig's angina, and one testicular carcinoma) were not considered to be related to use of mouthwash.\nOur findings do not support the use of Listerine Cool Mint as a way to prevent STI acquisition among high-risk populations.\nBelgian Research Foundation - Flanders (FWO 121\u00b700).\nCopyright \u00a9 2021 Elsevier Ltd. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "men", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 73}, {"term": "sex with men", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 95}, {"term": "HIV pre-exposure prophylaxis ( PReGo )", "negation": "affirmed", "UMLS": {}, "start": 103, "end": 141}, {"term": "PrEP", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 28}, {"term": "STI", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 43}, {"term": "sexual partners", "negation": "affirmed", "UMLS": {}, "start": 114, "end": 129}, {"term": "chlamydia", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 66}, {"term": "gonorrhoea", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 83}, {"term": "high-risk populations", "negation": "negated", "UMLS": {}, "start": 101, "end": 122}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Antibacterial mouthwash to prevent sexually transmitted infections in men who have sex with men taking HIV pre-exposure prophylaxis ( PReGo ) : a randomised , placebo-controlled , crossover trial .", "Evidence Elements": {"Participant": [{"term": "men", "negation": "affirmed", "UMLS": {}, "start": 70, "end": 73}, {"term": "sex with men", "negation": "affirmed", "UMLS": {}, "start": 83, "end": 95}, {"term": "HIV pre-exposure prophylaxis ( PReGo )", "negation": "affirmed", "UMLS": {}, "start": 103, "end": 141}], "Intervention": [{"term": "Antibacterial mouthwash", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 23, "has_chemical": [{"text": "antibacterial", "maps_to": "C0279516:antibacterials", "start": 0, "end": 13, "has_form": ["mouthwash"]}], "has_relation": "N/A"}], "Outcome": [{"term": "sexually transmitted infections", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 66}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Bacterial sexually transmitted infections ( STIs ) are highly prevalent among men who have sex with men who use HIV pre-exposure prophylaxis ( PrEP ) , which leads to antimicrobial consumption linked to the emergence of antimicrobial resistance .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "We aimed to assess use of an antiseptic mouthwash as an antibiotic sparing approach to prevent STIs .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "antiseptic mouthwash", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 49, "has_chemical": [{"text": "antiseptic", "maps_to": "C0003205:antiseptic", "start": 0, "end": 10, "has_form": ["mouthwash"]}], "has_relation": "N/A"}], "Outcome": [{"term": "STIs", "negation": "affirmed", "UMLS": {}, "start": 95, "end": 99}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "We invited people using PrEP who had an STI in the past 24 months to participate in this single-centre , randomised , double-blind , placebo-controlled , AB / BA crossover superiority trial at the Institute of Tropical Medicine in Antwerp , Belgium .", "Evidence Elements": {"Participant": [{"term": "PrEP", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 28}, {"term": "STI", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 43}], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Using block randomisation ( block size eight ) , participants were assigned ( 1:1) to first receive Listerine Cool Mint or a placebo mouthwash .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Listerine Cool Mint", "negation": "affirmed", "UMLS": {}, "start": 100, "end": 119, "has_chemical": [{"text": "listerine", "maps_to": "C0065081:listerine", "start": 0, "end": 9}], "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "They were required to use the study mouthwashes daily and before and after sex for 3 months each and to ask their sexual partners to use the mouthwash before and after sex .", "Evidence Elements": {"Participant": [{"term": "sexual partners", "negation": "affirmed", "UMLS": {}, "start": 114, "end": 129}], "Intervention": [{"term": "mouthwashes", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 47, "has_chemical": [{"text": "mouthwashes", "maps_to": "C0026647:mouthwashes", "start": 0, "end": 11, "has_form": ["mouthwashes"]}], "has_relation": "N/A"}, {"term": "mouthwash", "negation": "affirmed", "UMLS": {}, "start": 36, "end": 45, "has_relation": "N/A"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Participants were screened every 3 months for syphilis , chlamydia , and gonorrhoea at the oropharynx , anorectum , and urethra .", "Evidence Elements": {"Participant": [{"term": "chlamydia", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 66}, {"term": "gonorrhoea", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 83}], "Intervention": [], "Outcome": [{"term": "syphilis", "negation": "affirmed", "UMLS": {}, "start": 46, "end": 54}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "The primary outcome was combined incidence of these STIs during each 3-month period , assessed in the intention-to-treat population , which included all participants who completed at least the first 3-month period .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "combined incidence of these STIs", "negation": "affirmed", "UMLS": {}, "start": 24, "end": 56}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "Safety was assessed as a secondary outcome .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "Safety", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 6}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "METHODS", "Text": "This trial is registered with Clinicaltrials.gov , NCT03881007 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Between April 2 , 2019 , and March 13 , 2020 , 343 participants were enrolled : 172 in the Listerine followed by placebo ( Listerine-placebo ) group and 171 in the placebo followed by Listerine ( placebo-Listerine ) group .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Listerine followed by placebo ( Listerine-placebo )", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 142, "has_chemical": [{"text": "listerine", "maps_to": "C0065081:listerine", "start": 0, "end": 9}], "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 22, "end": 29}], "has_relation": "before (C0065081->C0032042)"}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "The trial was terminated prematurely because of the COVID-19 pandemic .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "151 participants completed the entire study , and 89 completed only the first 3-month period .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "31 participants withdrew consent , ten were lost to follow-up , and one acquired HIV .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "In the Listerine-placebo group , the STI incidence rate was 140\u00b74 per 100 person-years during the Listerine period , and 102\u00b76 per 100 person-years during the placebo period .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Listerine-placebo", "negation": "affirmed", "UMLS": {}, "start": 7, "end": 24, "has_procedure": [{"text": "listerine placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 17}], "has_relation": "N/A"}, {"term": "Listerine", "negation": "affirmed", "UMLS": {}, "start": 7, "end": 16, "has_chemical": [{"text": "listerine", "maps_to": "C0065081:listerine", "start": 0, "end": 9}], "has_relation": "N/A"}], "Outcome": [{"term": "STI incidence rate", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 55}], "Observation": [{"term": "140\u00b74 per 100 person-years", "negation": "affirmed", "UMLS": {}, "start": 60, "end": 86}, {"term": "102\u00b76 per 100 person-years", "negation": "affirmed", "UMLS": {}, "start": 121, "end": 147}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "Listerine-placebo", "has_procedure": [{"text": "listerine placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 17}], "has_relation": "N/A"}, "Observation": "140\u00b74 per 100 person-years", "Outcome": "STI incidence rate", "Count": ""}, {"Intervention": {"term": "Listerine", "has_chemical": [{"text": "listerine", "maps_to": "C0065081:listerine", "start": 0, "end": 9}], "has_relation": "N/A"}, "Observation": "140\u00b74 per 100 person-years", "Outcome": "STI incidence rate", "Count": ""}, {"Intervention": {"term": "Listerine-placebo", "has_procedure": [{"text": "listerine placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 17}], "has_relation": "N/A"}, "Observation": "102\u00b76 per 100 person-years", "Outcome": "STI incidence rate", "Count": ""}]}, {"Section": "FINDINGS", "Text": "In the placebo-Listerine arm , the STI incidence rate was 133\u00b79 per 100 person-years during the placebo period , and 147\u00b75 per 100 person-years during the Listerine period .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "placebo-Listerine", "negation": "affirmed", "UMLS": {}, "start": 7, "end": 24, "has_chemical": [{"text": "placebo listerine", "maps_to": "C0065081:listerine", "start": 0, "end": 17}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 7, "end": 14, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "STI incidence rate", "negation": "affirmed", "UMLS": {}, "start": 35, "end": 53}], "Observation": [{"term": "133\u00b79 per 100 person-years", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 84}, {"term": "147\u00b75 per 100 person-years", "negation": "affirmed", "UMLS": {}, "start": 117, "end": 143}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "placebo-Listerine", "has_chemical": [{"text": "placebo listerine", "maps_to": "C0065081:listerine", "start": 0, "end": 17}], "has_relation": "N/A"}, "Observation": "133\u00b79 per 100 person-years", "Outcome": "STI incidence rate", "Count": ""}, {"Intervention": {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}, "Observation": "133\u00b79 per 100 person-years", "Outcome": "STI incidence rate", "Count": ""}]}, {"Section": "FINDINGS", "Text": "We did not find that Listerine significantly reduced STI incidence ( IRR 1\u00b717 , 95 % CI 0\u00b784-1\u00b764 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Listerine", "negation": "negated", "UMLS": {}, "start": 21, "end": 30, "has_chemical": [{"text": "listerine", "maps_to": "C0065081:listerine", "start": 0, "end": 9}], "has_relation": "N/A"}], "Outcome": [{"term": "STI incidence", "negation": "negated", "UMLS": {}, "start": 53, "end": 66}], "Observation": [{"term": "significantly reduced", "negation": "negated", "UMLS": {}, "start": 31, "end": 52}], "Count": []}, "Evidence Propositions": []}, {"Section": "FINDINGS", "Text": "Numbers of adverse events were not significantly higher than at baseline and were similar while using Listerine and placebo .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Listerine", "negation": "affirmed", "UMLS": {}, "start": 102, "end": 111, "has_chemical": [{"text": "listerine", "maps_to": "C0065081:listerine", "start": 0, "end": 9}], "has_relation": "N/A"}, {"term": "placebo", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 123, "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Outcome": [{"term": "Numbers of adverse events", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 25}], "Observation": [{"term": "significantly higher", "negation": "negated", "UMLS": {}, "start": 35, "end": 55}, {"term": "similar", "negation": "negated", "UMLS": {}, "start": 82, "end": 89}], "Count": []}, "Evidence Propositions": [{"Intervention": [], "Observation": "significantly higher", "Outcome": "Numbers of adverse events", "Count": ""}, {"Intervention": [{"term": "Listerine", "has_chemical": [{"text": "listerine", "maps_to": "C0065081:listerine", "start": 0, "end": 9}], "has_relation": "N/A"}, {"term": "placebo", "has_procedure": [{"text": "placebo", "maps_to": "C0032042:placebos", "start": 0, "end": 7}], "has_relation": "N/A"}], "Observation": "similar", "Outcome": "Numbers of adverse events", "Count": ""}]}, {"Section": "FINDINGS", "Text": "Four serious adverse events ( one HIV-infection , one severe depression , one Ludwig 's angina , and one testicular carcinoma ) were not considered to be related to use of mouthwash .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "serious adverse events", "negation": "affirmed", "UMLS": {}, "start": 5, "end": 27}, {"term": "HIV-infection", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 47}, {"term": "severe depression", "negation": "affirmed", "UMLS": {}, "start": 54, "end": 71}, {"term": "Ludwig 's angina", "negation": "affirmed", "UMLS": {}, "start": 78, "end": 94}, {"term": "testicular carcinoma", "negation": "affirmed", "UMLS": {}, "start": 105, "end": 125}], "Observation": [], "Count": [{"term": "Four", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 4}, {"term": "one", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 33}, {"term": "one", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 33}, {"term": "one", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 33}, {"term": "one", "negation": "affirmed", "UMLS": {}, "start": 30, "end": 33}]}, "Evidence Propositions": []}, {"Section": "INTERPRETATION", "Text": "Our findings do not support the use of Listerine Cool Mint as a way to prevent STI acquisition among high-risk populations .", "Evidence Elements": {"Participant": [{"term": "high-risk populations", "negation": "negated", "UMLS": {}, "start": 101, "end": 122}], "Intervention": [{"term": "Listerine Cool Mint", "negation": "negated", "UMLS": {}, "start": 39, "end": 58, "has_chemical": [{"text": "listerine", "maps_to": "C0065081:listerine", "start": 0, "end": 9}], "has_relation": "N/A"}], "Outcome": [{"term": "STI acquisition", "negation": "negated", "UMLS": {}, "start": 79, "end": 94}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "FUNDING", "Text": "Belgian Research Foundation-Flanders ( FWO 121\u00b700 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2021 Elsevier Ltd . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}